Generex Biotechnology (NSDQ: GNBT) announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. The patent was granted to Antigen Express, the Generex subsidiary that is developing the vaccine.
According to Generex, it is “actively seeking” either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas.
Recently, Generex reported interim results, taken at the 13-month mark, from a Phase II trial of an Ii-Key modified peptide vaccine for breast cancer patients who are at high risk of relapse. Although the control arm experienced a 7% relapse rate, there were no relapses in the Ii-Key peptide arm in the first 13 months.
Generex is a drug delivery company that develops liquid formulations of drugs that are administered using the company’s RapidMist™ device. Drugs are delivered through the oral cavity, where they are absorbed through the lining of the inner mouth with no deposit in the lungs.
Antigen Express is a wholly owned subsidiary of Generex. It develops immunotherapeutics that treat malignant, infectious, allergic, and autoimmune diseases.
In October 2007, Generex / Antigen Express said it would begin clinical trials of the Ii-Key modified peptide vaccine in China, though the company has not made any announcements about the China trial in the last two and a half years.